0000862861--12-31 2024 Q1 false 0000862861 2024-01-01 2024-03-30 0000862861 2024-04-30 xbrli:shares 0000862861 2024-03-30 iso4217:USD 0000862861 2023-12-31 0000862861 us-gaap:RelatedPartyMember 2024-03-30 0000862861 us-gaap:RelatedPartyMember 2023-12-31 0000862861 jan:SeriesSMember 2024-03-30 iso4217:USD xbrli:shares 0000862861 jan:SeriesSMember 2023-12-31 0000862861 jan:SeriesA1Member 2024-03-30 0000862861 jan:SeriesA1Member 2023-12-31 0000862861 2023-01-01 2023-04-01 0000862861 2022-12-31 0000862861 2023-04-01 0000862861 jan:SeriesA1Member 2023-12-31 0000862861 jan:SeriesS1PreferredMember 2023-12-31 0000862861 us-gaap:CommonStockMember 2023-12-31 0000862861 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0000862861 us-gaap:RetainedEarningsMember 2023-12-31 0000862861 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-12-31 0000862861 us-gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-03-30 0000862861 us-gaap:CommonStockMember 2024-01-01 2024-03-30 0000862861 us-gaap:RestrictedStockUnitsRSUMember us-gaap:CommonStockMember 2024-01-01 2024-03-30 0000862861 us-gaap:RetainedEarningsMember 2024-01-01 2024-03-30 0000862861 jan:SeriesA1Member 2024-03-30 0000862861 jan:SeriesS1PreferredMember 2024-03-30 0000862861 us-gaap:CommonStockMember 2024-03-30 0000862861 us-gaap:AdditionalPaidInCapitalMember 2024-03-30 0000862861 us-gaap:RetainedEarningsMember 2024-03-30 0000862861 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-03-30 0000862861 jan:SeriesA1Member 2022-12-31 0000862861 jan:SeriesS1PreferredMember 2022-12-31 0000862861 us-gaap:CommonStockMember 2022-12-31 0000862861 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0000862861 us-gaap:RetainedEarningsMember 2022-12-31 0000862861 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-31 0000862861 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-04-01 0000862861 us-gaap:CommonStockMember 2023-01-01 2023-04-01 0000862861 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-01-01 2023-04-01 0000862861 us-gaap:RetainedEarningsMember 2023-01-01 2023-04-01 0000862861 jan:SeriesA1Member 2023-04-01 0000862861 jan:SeriesS1PreferredMember 2023-04-01 0000862861 us-gaap:CommonStockMember 2023-04-01 0000862861 us-gaap:AdditionalPaidInCapitalMember 2023-04-01 0000862861 us-gaap:RetainedEarningsMember 2023-04-01 0000862861 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-04-01 jan:segment 0000862861 jan:SoinTherapeuticsLLCMember jan:SeriesSConvertiblePreferredStockMember 2024-01-24 2024-01-24 0000862861 jan:SoinTherapeuticsLLCMember 2024-03-01 2024-03-31 0000862861 jan:SoinTherapeuticsLLCMember jan:BusinessAcquisitionConsiderationTrancheOneMember 2024-03-01 2024-03-31 0000862861 jan:SoinTherapeuticsLLCMember jan:BusinessAcquisitionConsiderationTrancheTwoMember 2024-03-01 2024-03-31 0000862861 jan:SoinTherapeuticsLLCMember jan:SoinAgreementConvertibleTrancheOneMember 2024-01-24 2024-01-24 0000862861 jan:SoinTherapeuticsLLCMember jan:SoinAgreementConvertibleTrancheOneMember 2022-12-28 2022-12-28 0000862861 jan:SoinAgreementConvertibleTrancheTwoMember jan:SoinTherapeuticsLLCMember 2024-01-24 2024-01-24 0000862861 jan:SoinAgreementConvertibleTrancheTwoMember jan:SoinTherapeuticsLLCMember 2022-12-28 2022-12-28 0000862861 jan:SoinTherapeuticsLLCMember jan:SoinAgreementConvertibleTrancheThreeMember 2024-01-01 2024-03-30 0000862861 jan:SoinTherapeuticsLLCMember jan:SoinAgreementConvertibleTrancheThreeMember 2022-12-28 2022-12-28 0000862861 jan:ARCAAndSubsidiariesMember jan:RecyclingSegmentMember us-gaap:SegmentDiscontinuedOperationsMember 2024-01-01 2024-03-30 0000862861 jan:ARCAAndSubsidiariesMember jan:RecyclingSegmentMember us-gaap:SegmentDiscontinuedOperationsMember 2023-01-01 2023-04-01 0000862861 jan:ARCAAndSubsidiariesMember jan:RecyclingSegmentMember us-gaap:SegmentDiscontinuedOperationsMember 2023-12-31 0000862861 jan:ARCAAndSubsidiariesMember jan:RecyclingSegmentMember us-gaap:SegmentDiscontinuedOperationsMember 2022-12-31 0000862861 jan:ARCAAndSubsidiariesMember jan:RecyclingSegmentMember us-gaap:SegmentDiscontinuedOperationsMember 2024-03-30 0000862861 jan:ARCAAndSubsidiariesMember jan:RecyclingSegmentMember us-gaap:SegmentDiscontinuedOperationsMember 2023-04-01 0000862861 us-gaap:SegmentContinuingOperationsMember jan:SoinIntangiblesMember 2024-03-30 0000862861 us-gaap:SegmentContinuingOperationsMember jan:SoinIntangiblesMember 2023-12-31 0000862861 us-gaap:SegmentContinuingOperationsMember jan:PatentsAndDomainsMember 2024-03-30 0000862861 us-gaap:SegmentContinuingOperationsMember jan:PatentsAndDomainsMember 2023-12-31 0000862861 us-gaap:SegmentContinuingOperationsMember 2024-03-30 0000862861 us-gaap:SegmentContinuingOperationsMember 2023-12-31 jan:patent 0000862861 jan:SeriesGConvertiblePreferredStockMember 2023-12-31 0000862861 jan:CommonShareEquivalentsMember 2023-12-31 0000862861 jan:SeriesGConvertiblePreferredStockMember 2024-01-01 2024-03-30 0000862861 jan:CommonShareEquivalentsMember 2024-01-01 2024-03-30 0000862861 jan:SeriesGConvertiblePreferredStockMember 2024-03-30 0000862861 jan:CommonShareEquivalentsMember 2024-03-30 0000862861 jan:ContinuingOperationsAndDiscontinuedOperationsMember 2024-03-30 0000862861 jan:ContinuingOperationsAndDiscontinuedOperationsMember 2023-12-31 0000862861 us-gaap:RelatedPartyMember jan:PromissoryNoteMember jan:IcgNoteMember jan:IcgNoteMember 2024-02-07 0000862861 us-gaap:RelatedPartyMember jan:PromissoryNoteMember jan:IcgNoteMember jan:IcgNoteMember 2024-03-25 2024-03-25 0000862861 us-gaap:RelatedPartyMember us-gaap:EquityUnitPurchaseAgreementsMember jan:PromissoryNoteMember jan:IcgNoteMember jan:IcgNoteMember 2024-03-25 2024-03-25 0000862861 us-gaap:RelatedPartyMember jan:LiveVentureIncorporatedMember jan:PromissoryNoteMember jan:LiveNoteMember 2024-02-07 0000862861 us-gaap:RelatedPartyMember jan:LiveVentureIncorporatedMember jan:PromissoryNoteMember jan:LiveNoteMember 2024-03-22 2024-03-22 0000862861 us-gaap:RelatedPartyMember us-gaap:EquityUnitPurchaseAgreementsMember jan:LiveVentureIncorporatedMember jan:PromissoryNoteMember jan:LiveNoteMember 2024-03-25 2024-03-25 0000862861 jan:SECComplaintMember 2021-08-02 jan:officer 0000862861 jan:SkybridgeLitigationMember jan:SkyBridgeAmericasMember 2017-01-25 2017-01-25 0000862861 jan:SkybridgeLitigationMember jan:SkyBridgeAmericasMember 2018-02-28 2018-02-28 0000862861 jan:SkybridgeLitigationMember jan:SkyBridgeAmericasMember 2021-02-01 2021-02-01 0000862861 jan:SkybridgeLitigationMember jan:SkyBridgeAmericasMember jan:InterestFeesAndCostsAndAttorneysFeesMember 2021-02-01 2021-02-01 0000862861 jan:SkybridgeLitigationMember jan:StatutoryInterestMember jan:SkyBridgeAmericasMember 2024-01-01 2024-03-30 0000862861 jan:SkybridgeLitigationMember jan:SkyBridgeAmericasMember 2024-01-01 2024-03-30 0000862861 jan:SkybridgeLitigationMember jan:SkyBridgeAmericasMember jan:LegalFeesMember 2024-01-01 2024-03-30 0000862861 jan:SkybridgeLitigationMember jan:PromissoryNoteMember us-gaap:SubsequentEventMember 2024-04-10 xbrli:pure 0000862861 jan:GeoTraqIncMember jan:GeoTraqLitigationMember 2021-04-09 2021-04-09 0000862861 jan:GeoTraqLitigationMember 2021-06-01 2021-06-01 jan:installment 0000862861 jan:GeoTraqIncMember jan:GeoTraqLitigationMember 2021-06-01 2021-06-01 0000862861 jan:GeoTraqLitigationMember jan:SeriesA1ConvertiblePreferredStockMember 2023-03-17 2023-03-17 0000862861 us-gaap:CommonStockMember jan:GeoTraqLitigationMember 2023-03-17 2023-03-17 0000862861 jan:GeoTraqLitigationMember jan:SeriesA1ConvertiblePreferredStockMember 2023-06-01 2023-06-01 0000862861 us-gaap:CommonStockMember jan:GeoTraqLitigationMember 2023-06-01 2023-06-01 0000862861 jan:GeoTraqLitigationMember jan:SeriesA1ConvertiblePreferredStockMember 2023-09-01 2023-09-01 0000862861 us-gaap:CommonStockMember jan:GeoTraqLitigationMember 2023-09-01 2023-09-01 0000862861 jan:GeoTraqLitigationMember jan:SeriesA1ConvertiblePreferredStockMember 2023-09-30 2023-09-30 0000862861 jan:AlixpartnersLlcMember jan:AlixpartnersLLCLitigationMember 2022-10-19 2022-10-19 0000862861 jan:AlixpartnersLlcMember jan:AlixpartnersLLCLitigationMember 2024-01-01 2024-03-30 0000862861 jan:AlixpartnersLlcMember jan:AlixpartnersLLCLitigationMember 2024-03-30 jan:tranche 0000862861 jan:Main270LLCLitigationMember jan:TrusteesMain270LlcMember 2024-01-01 2024-03-30 0000862861 jan:Main270LLCLitigationMember jan:TrusteesMain270LlcMember jan:ApplianceSmartIncMember 2024-01-01 2024-03-30 0000862861 jan:WestervilleSquareMember jan:WestervilleSquareLitigationMember 2024-01-01 2024-03-30 0000862861 jan:WestervilleSquareMember jan:WestervilleSquareLitigationMember 2023-06-04 2023-06-04 0000862861 jan:ApplianceSmartIncMember jan:OtherCommitmentsAndLitigationCasesMember 2024-03-30 0000862861 jan:OtherCommitmentsAndLitigationCasesMember 2017-12-30 jan:landlord 0000862861 jan:OtherCommitmentsAndLitigationCasesMember 2024-03-30 jan:guarantee 0000862861 jan:ApplianceSmartIncMember jan:OtherCommitmentsAndLitigationCasesMember 2023-12-31 0000862861 jan:ArticlesOfIncorporationMember 2024-03-30 0000862861 jan:ArticlesOfIncorporationMember 2023-01-01 2023-04-01 0000862861 jan:ArticlesOfIncorporationMember 2024-01-01 2024-03-30 0000862861 us-gaap:PrivatePlacementMember 2023-08-18 2023-08-18 0000862861 us-gaap:PrivatePlacementMember 2023-08-18 0000862861 jan:PreFundedWarrantsMemberMember us-gaap:PrivatePlacementMember 2023-08-18 0000862861 us-gaap:PrivatePlacementMember 2024-01-01 2024-03-30 0000862861 jan:A2023PlanMemberMember us-gaap:RestrictedStockUnitsRSUMember 2024-01-01 2024-03-30 0000862861 jan:A2023PlanMemberMember us-gaap:RestrictedStockUnitsRSUMember 2023-10-09 2023-10-09 0000862861 jan:A2023PlanMemberMember us-gaap:RestrictedStockUnitsRSUMember 2023-10-09 0000862861 us-gaap:RelatedPartyMember us-gaap:EquityUnitPurchaseAgreementsMember jan:IcgNoteMember 2024-02-23 jan:investor 0000862861 us-gaap:RelatedPartyMember us-gaap:EquityUnitPurchaseAgreementsMember 2024-02-23 2024-02-23 0000862861 us-gaap:RelatedPartyMember us-gaap:EquityUnitPurchaseAgreementsMember jan:IcgNoteMember 2024-02-23 2024-02-23 0000862861 us-gaap:RelatedPartyMember jan:IcgNoteMember 2024-02-23 0000862861 us-gaap:RelatedPartyMember jan:ThirdPartyExchangeForBrokerageServicesMember 2024-02-23 2024-02-23 0000862861 us-gaap:RelatedPartyMember jan:Mr.JonIsaacMember jan:IsaacConsultingAgreementMember 2024-03-04 2024-03-04 0000862861 us-gaap:RelatedPartyMember jan:PromissoryNoteMember jan:IcgNoteMember jan:IcgNoteMember 2024-03-22 2024-03-22 0000862861 jan:A2023PlanMemberMember 2024-03-30 0000862861 jan:Plan2016Member 2020-11-03 0000862861 jan:Plan2016Member 2020-11-04 0000862861 jan:Plan2016Member 2023-12-31 0000862861 jan:Plan2016Member 2024-03-30 0000862861 jan:Plan2011Member 2023-12-31 0000862861 jan:Plan2011Member 2024-03-30 0000862861 jan:Plan2011Member 2024-01-01 2024-03-30 0000862861 2023-01-01 2023-12-31 0000862861 us-gaap:EmployeeStockOptionMember 2024-01-01 2024-03-30 0000862861 us-gaap:EmployeeStockOptionMember 2023-01-01 2023-04-01 0000862861 us-gaap:EmployeeStockOptionMember 2023-04-01 0000862861 jan:SeriesA1ConvertiblePreferredStockMember 2024-01-01 2024-03-30 0000862861 jan:SeriesA1ConvertiblePreferredStockMember 2023-12-31 0000862861 jan:SeriesA1ConvertiblePreferredStockMember 2024-03-30 0000862861 jan:SoinTherapeuticsLLCMember jan:SeriesSConvertiblePreferredStockMember 2022-12-28 0000862861 jan:SoinTherapeuticsLLCMember jan:SeriesSConvertiblePreferredStockMember 2022-12-28 2022-12-28 0000862861 jan:SeriesSConvertiblePreferredStockMember 2023-12-31 0000862861 jan:SeriesSConvertiblePreferredStockMember 2024-03-30 0000862861 us-gaap:PreferredStockMember us-gaap:SeriesAPreferredStockMember 2024-01-01 2024-03-30 0000862861 us-gaap:PreferredStockMember us-gaap:SeriesAPreferredStockMember 2024-03-30 0000862861 jan:SeriesSPreferredStocksMember us-gaap:PreferredStockMember 2024-01-01 2024-03-30 0000862861 jan:SeriesSPreferredStocksMember us-gaap:PreferredStockMember 2024-03-30 0000862861 us-gaap:SegmentDiscontinuedOperationsMember 2024-01-01 2024-03-30 0000862861 us-gaap:SegmentDiscontinuedOperationsMember 2023-01-01 2023-04-01 0000862861 jan:BiotechnologyMember 2024-01-01 2024-03-30 0000862861 jan:BiotechnologyMember 2023-01-01 2023-04-01 0000862861 jan:ContinuingOperationsAndDiscontinuedOperationsMember 2024-01-01 2024-03-30 0000862861 jan:ContinuingOperationsAndDiscontinuedOperationsMember 2023-01-01 2023-04-01 0000862861 us-gaap:RelatedPartyMember jan:LiveVenturesIncorporatedMember 2024-01-01 2024-03-30 0000862861 us-gaap:RelatedPartyMember jan:LiveVenturesIncorporatedMember 2023-01-01 2023-04-01 0000862861 us-gaap:RelatedPartyMember jan:LiveVenturesIncorporatedMember 2024-03-30 utr:sqft 0000862861 us-gaap:RelatedPartyMember jan:NotesPayableWithLiveVenturesAndICGMember jan:PromissoryNoteMember jan:LiveVenturesAndICGNotesMember 2024-02-07 0000862861 us-gaap:RelatedPartyMember jan:NotesPayableWithLiveVenturesAndICGMember jan:PromissoryNoteMember jan:LiveVenturesAndICGNotesMember 2024-02-07 2024-02-07 0000862861 us-gaap:RelatedPartyMember jan:NotesPayableWithLiveVenturesAndICGMember jan:PromissoryNoteMember jan:LiveVenturesAndICGNotesMember 2024-03-30 0000862861 us-gaap:RelatedPartyMember jan:Mr.JonIsaacMember jan:IsaacConsultingAgreementMember 2024-03-04 jan:insurance_policy 0000862861 us-gaap:RelatedPartyMember jan:UniversalLifeInsurancePolicyPolicyOneMember jan:Mr.JonIsaacMember jan:IsaacConsultingAgreementMember 2024-03-04 0000862861 us-gaap:RelatedPartyMember jan:Mr.JonIsaacMember jan:UniversalLifeInsurancePolicyPolicyTwoMember jan:IsaacConsultingAgreementMember 2024-03-04 jan:trading_day 0000862861 us-gaap:RelatedPartyMember jan:Mr.JonIsaacMember jan:IsaacConsultingAgreementMember 2024-01-01 2024-03-30 0000862861 us-gaap:RelatedPartyMember jan:IsaacConsultingAgreementMember 2024-03-30
Table of Contents

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
o Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
For the quarterly period ended March 30, 2024
or
o Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Commission File No. 0-19621
JANONE INC.
(Exact name of registrant as specified in its charter)

Nevada (State or other jurisdiction of incorporation or organization) |  | 41-1454591 (I.R.S. Employer Identification No.)
325 E. Warm Springs Road, Suite 102 Las Vegas, Nevada (Address of principal executive offices) |  | 89119 (Zip Code)

702-997-5968
(Registrant’s telephone number, including area code)
Securities registered pursuant to Section 12(b) of the Act:

Title of each class |  | Trading Symbol(s) |  | Name of each exchange on which registered
Common Stock, $0.001 par value per share |  | JAN |  | The Nasdaq Stock Market LLC (The Nasdaq Capital Market)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports) and (2) has been subject to such filing requirements for the past 90 days. x Yes o No
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). x Yes o No
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act. (Check one)

Large accelerated filer | o |  | Accelerated filer | o
Non-accelerated filer | x |  | Smaller reporting company | x
Emerging growth company | o |  |  |

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). o Yes x No
As of April 30, 2024, there were 8,976,379 outstanding shares of the registrant’s common stock, with a par value of $0.001.

Table of Contents
JANONE INC.
INDEX TO FORM 10-Q

|  | Page
PART I. FINANCIAL INFORMATION |
Item 1. | Condensed Consolidated Financial Statements | 3
| Unaudited Condensed Consolidated Balance Sheets as of March 30, 202 4 and December 3 0, 202 3 | 3
| Unaudited Condensed Consolidated Statements of Operations and Comprehensive Income for the 13 weeks ended March 30, 202 4 and April 1, 202 3 | 4
| Unaudited Condensed Consolidated Statements of Cash Flows for the 13 weeks ended March 30, 202 4 and April 1, 202 3 | 5
| Unaudited Condensed Consolidated Statements of Stockholders’ Equity for the 13 weeks ended March 30, 202 4 and April 1, 202 3 | 6
| Notes to Unaudited Condensed Consolidated Financial Statements | 8
Item 2. | Management’s Discussion and Analysis of Financial Condition and Results of Operations | 22
Item 3. | Quantitative and Qualitative Disclosures About Market Risk | 25
Item 4. | Controls and Procedures | 26
PART II. OTHER INFORMATION |
Item 1. | Legal Proceedings | 28
Item 1A. | Risk Factors | 28
Item 2. | Unregistered Sales of Equity Securities and Use of Proceeds | 28
Item 3. | Defaults Upon Senior Securities | 28
Item 4. | Mine Safety Disclosures | 28
Item 5 | Other Information | 28
Item 6. | Exhibits | 28
SIGNATURES | 30

2

Table of Contents
PART I. FINANCIAL INFORMATION
ITEM 1. Condensed Consolidated Financial Statements
JANONE INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(Dollars in thousands, except per-share amounts)

| March 30, 2024 |  | December 30, 2023
| (Unaudited) |  |
Assets |  |  |
Cash and cash equivalents | $ | 61 |  |  | $ | 5 |
Trade and other receivables, net | 331 |  |  | 266 |
Prepaid expenses and other current assets | 799 |  |  | 75 |
Total current assets | 1,191 |  |  | 346 |
Intangible assets - Soin, net | 17,203 |  |  | 17,842 |
Other intangible assets, net | 4 |  |  | 4 |
Marketable securities | 180 |  |  | 286 |
Deposits and other assets | — |  |  | 9 |
Total assets | $ | 18,578 |  |  | $ | 18,487 |
Liabilities and Stockholders' Equity |  |  |
Liabilities: |  |  |
Accounts payable | $ | 2,034 |  |  | $ | 2,272 |
Accrued liabilities - other | 2,541 |  |  | 3,633 |
Due to Soin | 2,900 |  |  | — |
Related party notes payable | 600 |  |  | — |
Total current liabilities | 8,075 |  |  | 5,905 |
Deferred income taxes, net | 564 |  |  | 639 |
Related party note payable | 504 |  |  | 707 |
Notes payable | 1,806 |  |  | — |
Other noncurrent liabilities | — |  |  | 34 |
Total liabilities | 10,949 |  |  | 7,285 |
Commitments and contingencies (Note 12) |  |  |
Mezzanine equity |  |  |
Convertible preferred stock, series S - par value $0.001 per share 200,000 authorized, 100,000 and 100,000 shares issued and outstanding at March 30, 2024 and December 30, 2023, respectively | 3,856 |  |  | 14,510 |
Stockholders' equity: |  |  |
Preferred stock, series A - par value $0.001 per share 2,000,000 authorized, 193,730 and 193,730 shares issued and outstanding at March 30, 2024 and December 30, 2023, respectively | — |  |  | — |
Common stock, par value $0.001 per share, 200,000,000 shares authorized, 7,551,379 and 4,957,647 shares issued and outstanding at March 30, 2024 and at December 30, 2023, respectively | 5 |  |  | 3 |
Convertible preferred stock, series S - par value $0.001 per share 200,000 authorized, 100,000 and 100,000 shares issued and outstanding at March 30, 2024 and December 30, 2023, respectively | 7,993 |  |  | — |
Additional paid-in capital | 48,553 |  |  | 47,323 |
Accumulated deficit | (52,778) |  |  | (50,634) |
Total stockholders' equity (deficit) | 3,773 |  |  | (3,308) |
Total liabilities and stockholders' equity | $ | 18,578 |  |  | $ | 18,487 |

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.
3

Table of Contents
JANONE INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME
(UNAUDITED)
(Dollars in thousands, except per-share)

| For the Thirteen Weeks Ended
| March 30, 2024 |  | April 1, 2023
Revenues | $ | — |  |  | $ | — |
Cost of revenues | — |  |  | — |
Gross profit | — |  |  | — |
Operating expenses: |  |  |
Selling, general and administrative expenses | 1,806 |  |  | 1,099 |
Operating loss | (1,806) |  |  | (1,099) |
Other income (expense): |  |  |
Interest income (expense), net | (252) |  |  | 475 |
Unrealized loss on marketable securities | (190) |  |  | (247) |
Other income, net | 29 |  |  | (18) |
Total other income, net | (413) |  |  | 210 |
Income (loss) from continuing operations before provision for income taxes | (2,219) |  |  | (889) |
Income tax benefit | (75) |  |  | (227) |
Net income (loss) from continuing operations | (2,144) |  |  | (662) |
Gain (loss) from discontinued operations (including a $15.8 million gain on sale) | — |  |  | 13,976 |
Income tax provision for discontinued operations | — |  |  | 3,229 |
Net income (loss) from discontinued operations | — |  |  | 10,747 |
Net income | $ | (2,144) |  |  | $ | 10,085 |
Net income (loss) per share: |  |  |
Net loss per share from continuing operations, basic and diluted | $ | (0.34) |  |  | $ | (0.21) |
Net (loss) income per share from discontinued operations, basic and diluted | $ | — |  |  | $ | 3.36 |
Net (loss) income per share, basic and diluted | $ | (0.34) |  |  | $ | 3.15 |
Weighted average common shares outstanding: |  |  |
Basic | 6,308,331 |  | 3,199,061
Diluted | 6,308,331 |  | 3,199,061

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.
4

Table of Contents
JANONE INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(UNAUDITED)
(In thousands)

| For the Thirteen Weeks Ended
| March 30, 2024 |  | April 1, 2023
OPERATING ACTIVITIES: |  |  |
Net loss from continuing operations | $ | (2,144) |  |  | $ | (662) |
Adjustments to reconcile net loss to net cash provided by operating activities: |  |  |
Depreciation and amortization | 639 |  |  | 364 |
Stock based compensation expense | 345 |  |  | 8 |
Accretion of note receivable discount | — |  |  | (230) |
Unrealized loss on marketable securities | 190 |  |  | 247 |
Related party notes issued for shared services | 600 |  |  | — |
Change in deferred tax liability | (75) |  |  | — |
Changes in assets and liabilities: |  |  |
Accounts receivable, net of dispositions | (149) |  |  | (3) |
Prepaid expenses and other current assets, net of dispositions | 7 |  |  | 125 |
Accounts payable and accrued expenses, net of dispositions | 33 |  |  | 256 |
Deposits and other assets | 10 |  |  | 1 |
Operating cash flows provided by discontinued operations | — |  |  | 2,320 |
Net cash (used in) provided by operating activities | (544) |  |  | 2,426 |
INVESTING ACTIVITIES: |  |  |
Investing cash flows used in discontinued operations | — |  |  | (156) |
Net cash used in investing activities | — |  |  | (156) |
FINANCING ACTIVITIES: |  |  |
Proceeds from equity financing, net | 600 |  |  | 368 |
Payments on short-term notes payable | — |  |  | (205) |
Financing cash flows from discontinued operations | — |  |  | (2,212) |
Net cash provided by (used in) financing activities | 600 |  |  | (2,049) |
Effect of changes in exchange rate on cash and cash equivalents | — |  |  | 17 |
INCREASE IN CASH AND CASH EQUIVALENTS | 56 |  |  | 238 |
CASH AND CASH EQUIVALENTS, beginning of period | 5 |  |  | 115 |
LESS CASH OF DISCONTINUED OPERATIONS, end of period | — |  |  | — |
CASH AND CASH EQUIVALENTS, end of period | $ | 61 |  |  | $ | 353 |
Supplemental cash flow disclosures: |  |  |
Interest paid | $ | — |  |  | $ | 117 |

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.
5

Table of Contents
JANONE INC.
CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY
(UNAUDITED)
(Dollars in thousands)

| Series A-1 Preferred |  | Series S-1 Preferred |  | Common Stock |  | Additional Paid-in Capital |  | Accumulated Deficit |  | Accumulated Other Comprehensive Deficit |  | Total Stockholders' Equity
| Shares |  | Amount |  | Shares |  | Amount |  | Shares |  | Amount
Balance, December 30, 2023 | 193,730 |  | $ | — |  |  | 100,000 |  | $ | — |  |  | 4,957,647 |  | $ | 3 |  |  | $ | 47,323 |  |  | $ | (50,634) |  |  | $ | — |  |  | $ | (3,308) |
Share based compensation | — |  | — |  |  | — |  |  | — |  |  | — |  | — |  |  | 345 |  |  | — |  |  | — |  |  | 345 |
Reclassification of Series S stock to liability | — |  | — |  |  | — |  |  | — |  |  | — |  | — |  |  | (339) |  |  | — |  |  | — |  |  | (339) |
Reclassification of Series S stock to permanent equity | — |  | — |  |  | — |  |  | — |  |  | — |  | — |  |  | — |  |  | — |  |  | — |  |  | 7,993 |
Common stock issued for equity financing | — |  | — |  |  | — |  |  | — |  |  | 884,880 |  | 1 |  |  | 626 |  |  | — |  |  | — |  |  | 627 |
Common stock issued for consulting agreement | — |  | — |  |  | — |  |  | — |  |  | 200,000 |  | — |  |  | 232 |  |  | — |  |  | — |  |  | 232 |
Common stock issued in lieu of note payable obligations | — |  | — |  |  | — |  |  | — |  |  | 600,000 |  | 1 |  |  | 366 |  |  | — |  |  | — |  |  | 367 |
Common stock issued for RSU's granted | — |  | — |  |  | — |  |  | — |  |  | 908,852 |  | — |  |  | — |  |  | — |  |  | — |  |  | — |
Net loss | — |  | — |  |  | — |  |  | — |  |  | — |  | — |  |  | — |  |  | (2,144) |  |  | — |  |  | (2,144) |
Balance, March 30, 2024 | 193,730 |  | $ | — |  |  | 100,000 |  | $ | — |  |  | 7,551,379 |  | $ | 5 |  |  | $ | 48,553 |  |  | $ | (52,778) |  |  | $ | — |  |  | $ | 3,773 |

6

Table of Contents

| Series A-1 Preferred |  | Series S-1 Preferred |  | Common Stock |  | Additional Paid-in Capital |  | Accumulated Deficit |  | Accumulated Other Comprehensive Deficit |  | Total Stockholders' Equity
| Shares |  | Amount |  | Shares |  | Amount |  | Shares |  | Amount |
Balance, December 31, 2022 | 222,588 |  | $ | — |  |  | 100,000 |  | $ | — |  |  | 3,150,230 |  | $ | 2 |  |  | $ | 45,748 |  |  | $ | (42,822) |  |  | $ | (621) |  |  | $ | 2,307 |
Share based compensation | — |  | — |  |  | — |  | — |  | — |  | — |  |  | 8 |  |  | — |  |  | — |  |  | 8 |
Common stock issued for equity financing | — |  | — |  |  | — |  | — |  | 361,000 |  | 1 |  |  | 368 |  |  | — |  |  | — |  |  | 369 |
Common stock issued for legal settlement | — |  | — |  |  | — |  | — |  | 103,707 |  | — |  |  | 170 |  |  | — |  |  | — |  |  | 170 |
Other comprehensive income | — |  | — |  |  | — |  | — |  | — |  | — |  |  | — |  |  | — |  |  | 621 |  |  | 621 |
Net income | — |  | — |  |  | — |  | — |  | — |  | — |  |  | — |  |  | 10,085 |  |  | — |  |  | 10,085 |
Balance, April 1, 2023 | 222,588 |  | $ | — |  |  | 100,000 |  | $ | — |  |  | 3,614,937 |  | $ | 3 |  |  | $ | 46,294 |  |  | $ | (32,737) |  |  | $ | — |  |  | $ | 13,560 |

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.
7

Table of Contents
Note 1: Background
The accompanying consolidated financial statements include the accounts of JanOne Inc., a Nevada corporation, and its subsidiaries (collectively the “Company” or “JanOne”).
The Company had two operating segments – Biotechnology and Recycling. In connection with the sale of ARCA Recycling, Inc. (“ARCA Recycling”) during March 2023, the accounts for the Recycling segment have been presented as discontinued operations in the accompanying consolidated financial statements.
Biotechnology
During September 2019, JanOne, through its biotechnology segment, broadened its business perspectives to become a pharmaceutical company focused on finding treatments for conditions that cause severe pain and bringing to market drugs with non-addictive pain-relieving properties. Effective December 28, 2022, the Company acquired Soin Therapeutics LLC, a Delaware limited liability company (“STLLC”), and its product, a patent-pending, novel formulation of low-dose naltrexone, (“JAN123”). The product is being developed for the treatment of Complex Regional Pain Syndrome (CRPS), an indication that causes severe, chronic pain generally affecting the arms or legs. At present, there are no truly effective treatments for CRPS. Because of the relatively small number of patients afflicted with CRPS, the FDA has granted Orphan Drug Designation for any product approved for treatment of CRPS. This designation will provide the Company with tax credits for its clinical trials, exemption of user fees, and the potential of seven years of market exclusivity following approval. In addition, development of orphan drugs currently also involves smaller trials and quicker times to approval, given the limited number of patients available to study. However, there can be no assurance that the product will receive FDA approval or that it will result in material sales.
Recycling
ARCA Recycling was the Company’s Recycling segment and provides turnkey recycling services for electric utility energy efficiency programs in the United States. ARCA Canada Inc. (“ARCA Canada”) provides turnkey recycling services for electric utility energy efficiency programs in Canada. Customer Connexx, LLC (“Connexx”) provides call center services for ARCA Recycling and ARCA Canada. On March 9, 2023, retroactive to March 1, 2023, the Company entered into a Stock Purchase Agreement with VM7 Corporation, a Delaware corporation, under which the Buyer agreed to acquire all of the outstanding equity interests of (a) ARCA Recycling, Inc., a California corporation, (b) Customer Connexx LLC, a Nevada limited liability company, and (c) ARCA Canada Inc., a corporation organized under the laws of Ontario, Canada (“ARCA Canada”; and, together with ARCA and Connexx, the “Subsidiaries”). The principal of the Buyer is Virland A. Johnson, our Chief Financial Officer. The sale of all of the outstanding equity interests of the Subsidiaries to the Buyer under the Purchase Agreement was consummated simultaneously with the execution of the Purchase Agreement (see Note 17). The Company's Board of Directors unanimously approved the Purchase Agreement and the Disposition Transaction. In connection with the disposition of ARCA Recycling, accounts for the Recycling segment have been presented as discontinued operations in the accompanying consolidated financial statements (see Note 4).
The Company reports on a 52- or 53-week fiscal year. The Company’s 2023 fiscal year (“2023”) ended on December 30, 2023, and the current fiscal year (“2024”) will end on December 28, 2024.
Going concern
The accompanying financial statements have been prepared under the assumption that the Company will continue as a going concern. Such assumption contemplates the realization of assets and satisfaction of liabilities in the normal course of business, however, the issues described below raise substantial doubt about the Company’s ability to do so.
The Company currently faces a challenging competitive environment and is focused on improving its overall profitability and liquidity, which includes managing expenses. The Company reported a net loss from continuing operations of approximately $2.1 million for the 13 weeks ended March 30, 2024. Additionally, as of March 30, 2024, the Company has total current assets of approximately $1.2 million and total current liabilities of approximately $8.1 million resulting in a net negative working capital of approximately $6.9 million. Cash used in operations from continuing operations was approximately $544,000. Additionally, stockholders' equity, as of March 30, 2024, is approximately $3.8 million.
The Company intends to raise funds to support future development of JAN 123 and JAN 101 either through capital raises or structured arrangements. However, the success of such funding cannot be assured.
8

Table of Contents
The ability of the Company to continue as a going concern is dependent upon the success of future capital raises or structured settlements to fund the required testing to obtain FDA approval of JAN 123 and JAN 101, as well as to fund its day-to-day operations. Such approval is contingent on several factors and no assurance can be provided that approval will be obtained. The accompanying financial statements do not include any adjustments that might be necessary should the Company be unable to continue as a going concern. While the Company will actively pursue these additional sources of financing, management cannot make any assurances that such financing will be secured or FDA approvals will be obtained.
Note 2: Summary of Significant Accounting Policies
B asis of Presentation
The accompanying unaudited condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the U.S. (“U.S. GAAP”) and with the instructions to Form 10-Q and Article 10 of Regulation S-X for interim financial information. Accordingly, these financial statements do not include all of the information and notes required for complete financial statements prepared in conformity with U.S. GAAP. In our opinion, all adjustments, consisting of normal recurring adjustments, considered necessary for a fair presentation have been included. However, the Company’s results of operations for the interim periods presented are not necessarily indicative of the results that may be expected for the full year. For further information, refer to the consolidated financial statements and notes thereto included in our Form 10-K for the fiscal year ended December 30, 2023.
Principles of Consolidation
The accompanying consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation.
Use of Estimates
The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumption that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.
Significant estimates made in connection with the accompanying consolidated financial statements include the fair value in connection with the Series S convertible preferred stock issued in the Soin merger, valuation allowance against deferred tax assets, and estimated useful lives for intangible assets.
Financial Instruments
Financial instruments consist primarily of cash equivalents, trade and other receivables, and obligations under accounts payable, accrued expenses and notes payable. The carrying amounts of cash equivalents, trade receivables and other receivables, accounts payable, accrued expenses and short-term notes payable approximate fair value because of the short maturity of these instruments.
Recently Issued Accounting Pronouncements
In November 2023, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update ("ASU") 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures ("ASU 2023-07"). ASU 2023-07 requires, among other updates, enhanced disclosures about significant segment expenses that are regularly provided to the CODM, as well as the aggregate amount of other segment items included in the reported measure of segment profit or loss. ASU 2023-07 is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, and requires retrospective adoption. Early adoption is permitted. The Company is evaluating the impact of this guidance on its consolidated financial statements and related disclosures.
In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures ("ASU 2023-09"). ASU 2023-09 requires enhanced annual disclosures regarding the rate reconciliation and income taxes paid information. ASU 2023-09 is effective for fiscal years beginning after December 15, 2024, and may be adopted on a prospective or retrospective basis. Early adoption is permitted. The Company is evaluating the impact of this guidance on its consolidated financial statements and related disclosures.
9

Table of Contents
Note 3: Mergers and Acquisitions
Soin Pharmaceuticals
Effective January 24, 2024, the Company, Amol Soin (“Dr. Soin”), and Soin Therapeutics LLC, a wholly-owned subsidiary of the Company that was had acquired from Dr. Soin entered into an amendment (the “Soin Amendment”) to the parties’ Agreement and Plan of Merger that was dated as of December 28, 2022 (the “Soin Agreement”). With reference to the Soin Agreement, the parties to the Soin Amendment agreed that the $3.0 million convertible tranche (the first of the three original conversion tranches under the Soin Agreement) would be payable to Dr. Soin in cash rather than through his conversion of shares of the Series S Convertible Preferred Stock (the “Soin Preferred”) that constituted the consideration under the Soin Agreement. We tendered the first $100,000 amended tranche cash payment to Dr. Soin in March 2024; the second amended tranche cash payment to Dr. Soin, also in the amount of $100,000, is due on July 1, 2024; and the third amended tranche cash payment to Dr. Soin, in the amount of $2.8 million, is due on December 31, 2024. During the pendency of the amended cash tranche period, Dr. Soin agreed that he would not convert any of his shares of Soin Preferred. After we have tendered the second and third amended tranche cash payments to Dr. Soin, his conversion rights for the second and third original conversion tranches will remain convertible under the original provisions of the Soin Agreement and the related Certificate of Designation for the Soin Preferred. If we do not tender the second and third amended tranche cash payments to Dr. Soin, we agreed that we will transfer to him the membership interests of Soin Therapeutics LLC, and he will transfer to us the shares of Soin Preferred for cancellation.
In connection with the Soin Amendment, the Company reclassified the $3.0 million convertible tranche, originally valued at approximately $2.7 million on our balance sheet, from mezzanine equity to current liabilities, and reclassified the $10.0 million convertible tranche, originally valued at approximately $8.0 million on our balance sheet, to permanent equity. As of March 30, 2024, the outstanding balance in mezzanine equity relates to the $17.0 million convertible tranche originally valued at approximately $3.9 million.
Note 4: Discontinued Operations
On March 9, 2023, the Company discontinued operations of its Recycling segment as follows:
On March 9, 2023, the Company executed a Stock Purchase Agreement with VM7 Corporation, a Delaware corporation, under which, as of March 1, 2023, the Buyer agreed to acquire all of the outstanding equity interests of (a) ARCA Recycling, Inc., a California corporation, (b) Customer Connexx LLC, a Nevada limited liability company, and (c) ARCA Canada Inc., a corporation organized under the laws of Ontario, Canada (“ARCA Canada”; and, together with ARCA and Connexx, the “Subsidiaries”). The principal of the Buyer is Virland A. Johnson, our Chief Financial Officer. The sale of all of the outstanding equity interests of the Subsidiaries to the Buyer under the Purchase Agreement was consummated simultaneously with the execution of the Purchase Agreement. As of March 30, 2024 and December 30, 2023, no Recycling assets or liabilities were included in discontinued operations.
10

Table of Contents
In accordance with the provisions of ASC 205-20, the Company has not included in the results of continuing operations the results of operations of the discontinued operations in the consolidated statements of operations and comprehensive income (loss). The results of operations for these entities for the 13 weeks ended March 30, 2024 and April 1, 2023 have been reflected as discontinued operations in the consolidated statements of operations and comprehensive income (loss) and consist of the following:

| 13 weeks ended
| March 30, 2024 |  | April 1, 2023
Revenues | $ | — |  |  | $ | 3,795 |
Cost of revenues | — |  |  | 3,992 |
Gross profit | — |  |  | (197) |
Operating expenses from discontinued operations: |  |  |
Selling, general and administrative expenses | $ | — |  |  | $ | (14,355) |
Total operating income from discontinued operations | — |  |  | (14,355) |
Operating income from discontinued operations | — |  |  | 14,158 |
Other expense from discontinued operations |  |  |
Interest expense, net | — |  |  | (181) |
Other expense, net | — |  |  | (1) |
Total other expense, net | — |  |  | (182) |
Income before provision for income taxes from discontinued operations | — |  |  | 13,976 |
Income tax provision | — |  |  | 3,229 |
Net income from discontinued operations | $ | — |  |  | $ | 10,747 |

11

Table of Contents
In accordance with the provisions of ASC 205-20, the Company has separately reported the cash flow activity of the discontinued operations in the consolidated statements of cash flows. The cash flow activity from discontinued operations for the 13 weeks ended March 30, 2024 and April 1, 2023 have been reflected as discontinued operations in the consolidated statements of cash flows and consist of the following:

| 13 weeks ended
| March 30, 2024 |  | April 1, 2023
DISCONTINUED OPERATING ACTIVITIES: |  |  |
Net income (loss) from discontinued operations | — |  |  | 10,747 |
Depreciation and amortization | — |  |  | 96 |
Amortization of debt issuance costs | — |  |  | 11 |
Amortization of right-of-use assets | — |  |  | 53 |
Change in deferred taxes | — |  |  | 3,229 |
Gain on sale of ARCA, net of cash | — |  |  | (15,967) |
Changes in assets and liabilities: |  |  |
Accounts receivable | — |  |  | 2,932 |
Inventories | — |  |  | 299 |
Prepaid expenses and other current assets | — |  |  | 55 |
Accounts payable and accrued expenses | — |  |  | 866 |
Other assets | — |  |  | (1) |
Net cash provided by (used in) operating activities from discontinued operations | $ | — |  |  | $ | 2,320 |
DISCONTINUED INVESTING ACTIVITIES: |  |  |
Purchases of property and equipment | — |  |  | (123) |
Purchase of intangible assets | — |  |  | (33) |
Net cash used in investing activities from discontinued operations | $ | — |  |  | $ | (156) |
DISCONTINUED FINANCING ACTIVITIES: |  |  |
Proceeds from note payable | — |  |  | 5,162 |
Payment on related party note | — |  |  | (38) |
Payments on short term notes payable | — |  |  | (7,291) |
Payments on notes payable | — |  |  | (45) |
Net cash used in financing activities from discontinued operations | $ | — |  |  | $ | (2,212) |
Effect of changes in exchange rate on cash and cash equivalents | — |  |  | (5) |
DECREASE IN CASH AND CASH EQUIVALENTS | — |  |  | (53) |
CASH AND CASH EQUIVALENTS, beginning of period | — |  |  | 53 |
CASH AND CASH EQUIVALENTS, end of period | $ | — |  |  | $ | — |

Note 5: Trade and other receivables
The Company’s trade and other receivables as of March 30, 2024 and December 30, 2023, respectively, were as follows (in $000’s):

| March 30, 2024 |  | December 30, 2023
Interest receivable - SPYR | $ | 251 |  |  | $ | 266 |
Other receivables | 80 |  |  | — |
Trade and other receivables, net | $ | 331 |  | 331000 | $ | 266 |

12

Table of Contents
Note 6: Prepaids and other current assets
Prepaids and other current assets as of March 30, 2024 and December 30, 2023 consist of the following (in $000’s):

| March 30, 2024 |  | December 30, 2023
Prepaid consulting agreement | $ | 732 |  |  | $ | 3 |
Prepaid insurance | 2 |  |  | 72 |
Prepaid other | $ | 65 |  |  | — |
Total prepaid expenses and other current assets | $ | 799 |  |  | $ | 75 |

Note 7: Intangible Assets
Intangible assets as of March 30, 2024 and December 30, 2023 consist of the following (in $000’s):

| March 30, 2024 |  | December 30, 2023
Soin intangibles * | $ | 19,293 |  |  | $ | 19,293 |
Patents and domains | 4 |  |  | 4 |
Intangible assets | 19,297 |  |  | 19,297 |
Less accumulated amortization | (2,090) |  |  | (1,451) |
Total intangible assets | $ | 17,207 |  |  | $ | 17,846 |

*The Soin intangibles acquired by the Company consist of the following:
1.Two pending patents and one approved patent related to the methods of using low-dose Naltrexone to treat chronic pain;
2.Final formula for Naltrexone; and
3.Orphan drug designation as approved by the FDA.
Intangible amortization expense was $639,000 and $363,000 for the 13 weeks ended March 30, 2024 and April 1, 2023, respectively.
Note 8: Marketable Securities
Marketable securities consist of the following (in $000’s, except shares):

| Series G Convertible Preferred Shares |  | Common Shares Equivalent |  | Amount
Beginning Balance, December 30, 2023 | 9,224 |  | 952,442,000 |  | $ | 286 |
Securities received | 8,469 |  | 846,900,000 |  | 84 |
Mark-to-market | — |  | — |  | (190) |
Ending Balance, March 30, 2024 | 17,693 |  | 1,799,342,000 |  | 180

Note 9: Deposits and other assets
Deposits and other assets as of March 30, 2024 and December 30, 2023 consist of the following (in $000’s):

| March 30, 2024 |  | December 30, 2023
Other | $ | — |  |  | $ | 9 |
Total deposits and other assets | $ | — |  |  | $ | 9 |

13

Table of Contents
Note 10: Accrued Liabilities
Accrued liabilities as of March 30, 2024 and December 30, 2023 consist of the following (in $000’s):

| March 30, 2024 |  | December 30, 2023
Compensation and benefits | $ | 58 |  |  | $ | 37 |
Accrued guarantees | 1,983 |  |  | 3,049 |
Accrued taxes | 103 |  |  | 102 |
Accrued litigation settlement | 397 |  |  | 397 |
Other | — |  |  | 48 |
Total accrued expenses | $ | 2,541 |  |  | $ | 3,633 |

Note 11: Debt
On February 7, 2024, the Company amended its outstanding related party promissory obligations (the “ICG Note”) in favor of Isaac Capital Group (“ICG”) to add a convertibility provision. In accordance with Nasdaq Rules, the per-share conversion price was set at $0.61, subject to standard adjustments for (i) stock dividends and splits, (ii) subsequent rights offerings, and (iii) pro rata distributions. The Company’s board of directors provided its approvals of the amendments on February 7, 2024. On March 6, 2024, ICG entered into a Note Purchase Agreement with an otherwise unaffiliated third party, under which the third party acquired the ICG Note. The terms and conditions of the ICG Note were not modified in connection with its acquisition by the third party. The principal amount of the ICG Note on the date of acquisition was approximately $1.2 million. On March 25, 2024, the third party converted $183,000 of the Company's obligation under the ICG Note into 300,000 shares of the Company's common stock. As of March 30, 2024, the amount outstanding on the ICG Note was approximately $987,000.
On February 7, 2024, the Company amended its outstanding related party promissory obligations (the “Live Note”) in favor of Live Ventures Incorporated (“Live”) to add a convertibility provision. In accordance with Nasdaq Rules, the per-share conversion price for each obligation, as amended, was set at $0.61, subject to standard adjustments for (i) stock dividends and splits, (ii) subsequent rights offerings, and (iii) pro rata distributions. The Company’s board of directors provided its final approvals of the amendments on February 7, 2024. On March 6, 2024, Live entered into a Note Purchase Agreement with with another otherwise unaffiliated third party, under which under which the third party acquired the Live Note. The terms and conditions of the acquired Live Note were not modified in connection with its acquisition by the third party. The principal amount of the Live Note on the date of acquisition was approximately $1.0 million. On March 22, 2024, the third party converted $183,000 of the Company's obligation under the Live Note into 300,000 shares of the Company's common stock. As of March 30, 2024, the amount outstanding on the Live Note was approximately $819,000.
Note 12: Commitments and Contingencies
Litigation
SEC Complaint
On August 2, 2021, the U.S. Securities and Exchange Commission (“SEC”) filed a civil complaint (the “SEC Complaint”) in the United States District Court for the District of Nevada naming the Company and one of its executive officers, Virland Johnson, the Company's Chief Financial Officer, as defendants (collectively, the “Defendants”).
The SEC Complaint alleges financial, disclosure and reporting violations against the Company and the executive officer under Section 10(b) of the Securities Exchange Act of 1934 (the “Exchange Act”) and Rule 10b-5. The SEC Complaint also alleges various claims against the executive officer under Sections 13(a), 13(b)(2)(A), 13(b)(2)(B) and 13(b)(5) of the Exchange Act and Rules 12b-20, 13a-1, 13a-13, 13a-14, 13b2-1, and 13b2-2. The SEC seeks permanent injunctions and civil penalties against the Defendants, and an officer-and-director bar against the executive officer. The foregoing is only a general summary of the SEC Complaint, which may be accessed on the SEC’s website at https://www.sec.gov/litigation/litreleases/2021/lr25155.htm.
The Company continues to assert that the SEC’s pursuit of this matter will not result in any benefit to investors and instead will only serve as a distraction from its core business. On October 1, 2021, the Company, filed a motion with the court to dismiss the complaint. The SEC filed its response opposing the motions on November 1, 2021.On September 7, 2022, the motions to dismiss were denied by the court. Pursuant to the automatic stay of proceedings under the Private Securities
14

Table of Contents
Litigation Reform Act, all discovery was stayed pending the motions to dismiss and continues to be stayed pending the June 23, 2023 mediation to which all of the parties have agreed. As of the date of these financial statements, the Company and the SEC have reached a settlement agreement in principal, the written agreement for which was executed by the Company and the SEC and was filed with the Clerk of the Court to be signed by the judge.
Skybridge
On December 29, 2016, the Company served a Minnesota state court complaint for breach of contract on Skybridge Americas, Inc. (“SA”), the Company’s primary call center vendor throughout 2015 and most of 2016. The Company sought damages in the millions of dollars as a result of alleged overcharging by SA and lost client contracts. On January 25, 2017, SA served a counterclaim for unpaid invoices in the amount of approximately $460,000 plus interest and attorneys’ fees. On March 29, 2017, the Hennepin County district court (the “District Court”) dismissed the Company’s breach of contract claim based on SA’s overuse of its Canadian call center but permitted the Company’s remaining claims to proceed. Following motion practice, on January 8, 2018 the District Court entered judgment in SA’s favor, which was amended as of February 28, 2018, for a total amount of approximately $614,000, including interest and attorneys’ fees. On March 4, 2019, the Minnesota Court of Appeals (the “Court of Appeals”) ruled and (i) reversed the District Court’s judgment in favor of Skybridge on the call center location claim and remanded the issue back to the District Court for further proceedings, (ii) reversed the District Court’s judgment in favor of Skybridge on the net payment issue and remanded the issue to the District Court for further proceedings, and (iii) affirmed the District Court’s judgment in Skybridge’s favor against the Company’s claim that Skybridge breached the contract when it failed to meet the service level agreements. As a result of the decision by the Court of Appeals, the District Court’s award of interest and attorneys’ fees, etc. was reversed. The Company and SA held a mediation session in July 2020. Trial was held in August 2020 and on February 1, 2021, the District Court assessed damages against the Company in the amount of approximately $715,000 plus interest, fees, and costs and attorneys’ fees of $475,000. In subsequent proceedings, the Appeals Court affirmed the District Court judgment. Of the total amount awarded to SA, less the funds that the Company had previously deposited with the District Court, SA remains entitled to approximately $422,000 of statutory interest, which obligation has been assumed by the Buyer in connection with the ARCA and Subsidiaries Disposition transaction. On April 10, 2024, SA sold its judgment to an otherwise unaffiliated third party for the face value of the judgment and the interest accrued thereon through that date (an aggregate of $433,920.03), plus accrued legal fees (in the amount of $18,123.50) to which SA was entitled in accordance with the terms of the underlying agreement with the Company and with the judgment. The purchaser agreed to forbear from enforcing the judgment, subject to the Company’s repayment or his conversion thereof. In connection with the third-party’s forbearance, the Company issued its promissory note to such person in the initial principal amount of 147,956.47, which bears interest at the rate of 10% per annum, and, as with the underlying judgment, is convertible into shares of the Company’s common stock at a fixed per-share conversion price of $2.60.
GeoTraq
On or about April 9, 2021, GeoTraq, Gregg Sullivan, Tony Isaac, and we, among others, resolved all of their claims that related to, among other items, the Company's acquisition of GeoTraq in August 2017, all post-acquisition activities, and Mr. Sullivan’s post-acquisition employment relationship with GeoTraq (all of such claims, the “GeoTraq Matters”). The resolution was effectuated through the parties’ execution and delivery of a Settlement Agreement and Mutual Agreement of Claims (the “GeoTraq Settlement Agreement”).
Under the terms of the Settlement Agreement, the Company, on its own behalf and on behalf of GeoTraq and Mr. Isaac, agreed to tender to Mr. Sullivan an aggregate of $1.95 million (the “GeoTraq Settlement Consideration”) in the following manner: (i) $250,000, which was tendered in cash on or about the date of the Settlement Agreement and (ii) up to 10 quarterly installments of not less than $170,000 that commenced on June 1, 2021, and continued not less frequently than every three months thereafter (the “GeoTraq Installments”). The Company may tender the GeoTraq Installments in cash or in the equivalent value of shares of its common stock (the value of the shares to be determined by a formula set forth in the Settlement Agreement), in either case at the Company's discretion. The Company may also prepay one or more GeoTraq Installments in full or in part at any time or from time to time either in cash or in shares of its common stock (a “GeoTraq Prepayment”). If the Company elected to prepay one or more GeoTraq Installments with shares of its common stock, Mr. Sullivan reserved the right not to consent to a tender thereof in excess of 50% of the value of that specific GeoTraq Prepayment; however, Mr. Sullivan was restricted in the reasons for which he can refuse to provide his written consent. The number of shares of the Company's common stock to be issued upon any GeoTraq Prepayment is determined by a different formula than the one to be utilized for a GeoTraq Installment. On March 17, 2023, the Company converted 5,185 of Mr. Sullivan’s Series A-1 Preferred shares and issued 103,707 shares of the Company's common stock as payment for its quarterly installment. On June 1, 2023, the Company converted 7,697 of Mr. Sullivan’s Series A-1 Preferred shares into 153,941 shares of the Company’s common stock in payment of its June 30, 2023 quarterly installment. On September 1, 2023, the Company converted 14,471 of Mr. Sullivan’s Series A-1 Preferred shares into 289,421 shares of the Company’s common stock in payment of its September 30, 2023 quarterly installment. As of September 30, 2023, the full balance due
15

Table of Contents
under the Settlement Agreement had been repaid and the remaining 1,505 shares of Mr. Sullivan’s Series A-1 Preferred shares were returned to the Company for cancellation without any further consideration.
The parties to the Settlement Agreement released and forever discharged one another from any and all known and unknown claims that were asserted or could have been asserted arising out of the GeoTraq Litigation Matters.
Alixpartners, LLC
On October 19, 2022, Alixpartners, LLC filed a complaint in the Supreme Court of the State of New York, County of New York, styled Alixpartners, LLC, plaintiff/petitioner, against JanOne Inc., Index No. 653877/2022. Plaintiff alleged the breach of an agreement and sought damages in the amount of approximately $345,000. The Company denied that obligation. After extensive negotiations, the parties reached a settlement, pursuant to which the Company agreed to pay to Alixpartners the sum of $125,000 in two tranches and to provide a confession of judgment in its favor in the amount of approximately $450,000, which represented the amount sought in the complaint plus interest thereon. The confession of judgment will be null and void and the complaint will be dismissed with prejudice upon the Company tendering both tranches timely. The Company tendered both settlement payments in May 2023, and the complaint was subsequently dismissed.
Sieggreen
In a matter pending in the United States District Court for the District Of Nevada, Case No. 2:21-cv-01517-CDS-EJY, styled as Sieggreen, Individually and On Behalf of All Others Similarly Situated, Plaintiff, v. Live Ventures Incorporated, Jon Isaac, and Virland A. Johnson, Defendants, the Company was added as a defendant on March 6, 2023, and was served on March 23, 2023. Plaintiff has alleged causes of action against the Company for (i) violation of Section 10(b) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder and (ii) violation of Section 10(b) of the Securities Exchange Act of 1934 and Rules 10b-5(a) and 10b-5(c) promulgated thereunder. In June 2023 the Company filed a Motion to Dismiss, regarding which, as of the date of these financial statements, the Court has not ruled. The Company strongly disputes and denies all of the allegations contained therein and will continue to defend itself vigorously against the claims.
Main/270
The Company is a defendant in an action filed on April 11, 2022, in the U.S. District Court Southern District of Ohio, Eastern Division, styled, Trustees Main/270, LLC, Plaintiff, vs ApplianceSmart, Inc. and JANONE, Inc., Defendant, Case no.: 2:22-cv-01938-ALM-EPD. The Company was a guarantor of the lease between the Plaintiff and ApplianceSmart, Inc. Plaintiff alleged a cause of action against the Company in respect of the guaranty and seeks approximately $90,000 therefor. Plaintiff also seeks approximately $1,420,000 against ApplianceSmart and the Company on a joint and several basis. The Company and Live Ventures Incorporated (“Live Ventures”), the parent company of ApplianceSmart, have an agreement, pursuant to which all attorney's fees and any judgment will be divided equally between the parties. Nevertheless, the Company does not believe that it is obligated to Plaintiff in that amount and the parties continue to negotiate a potential settlement.
Westerville Square
In an attempt to recover payments due under a lease, in 2021, Westerville Square, Inc., as the landlord, initiated a civil action against the Company, styled Westerville Square, Inc. v. Appliance Recycling Centers Of America, Inc., et al., in the Court of Common Pleas of Franklin County, Ohio, Case No. 19 CV 8627. The case was stayed during the bankruptcy proceedings of ApplianceSmart, Inc., and was reinstated on June 7, 2021. The landlord is currently seeking $120,000, which amount is disputed by the Company. Effective June 4, 2023, the parties settled the matter, pursuant to which settlement the Company tendered the sum of $110,000 to the landlord, the parties entered into a Settlement Agreement and Release, and the case was dismissed with prejudice.
Other Commitments
On December 30, 2017, the Company disposed of its retail appliance segment and sold ApplianceSmart to Live Ventures, a related party. In connection with that sale, as of January 2, 2021, the Company accrued an aggregate amount of future real property lease payments of approximately $767,000 which represented amounts guaranteed or which may have been owed under certain lease agreements to three third party landlords in which the Company either remained the counterparty, was a guarantor, or had agreed to remain contractually liable under the lease (“ApplianceSmart Leases”). A final decree was issued by the court on February 28, 2022, upon the full satisfaction of the Plan, at which time ApplianceSmart emerged from Chapter 11. During the year ended December 30, 2023, the Company reversed approximately $637,000 of the
16

Table of Contents
accrual, as the Company is no longer liable for two of these guarantees upon ApplianceSmart's emergence from bankruptcy. As of December 30, 2023, a balance of approximately $130,000 remains as an accrued liability due to an ongoing dispute concerning one of the leases. The Company and Live Ventures have agreed to divide in half between them any ultimate balance owing thereunder and any attorneys’ fees expended in relation thereto.
The Company is party from time to time to other ordinary course disputes that we do not believe to be material to our financial condition as of March 30, 2024.
Note 13: Stockholders’ Equity
Common Stock: Our Articles of Incorporation authorize 200,000,000 shares of common stock that may be issued from time to time having such rights, powers, preferences and designations as the Board of Directors may determine. During the 13 weeks ended March 30, 2024 and April 1, 2023, no shares of common stock were issued in lieu of professional services.
On August 18, 2023, the Company entered into a Securities Purchase Agreement with a certain institutional investor for the sale by the Company in a registered direct offering of: (i) 418,000 shares of the Company’s common stock, par value $0.001 per share, at an offering price of $0.8811 per share and (ii) pre-funded warrants exercisable for up to 481,348 shares of Common Stock to the Investor at an offering price equal to $0.8801 per pre-funded Warrant. In connection with the Securities Purchase Agreement, during the 13 weeks ended March 30, 2024, the Company issued 27,738 shares of its common stock to three third-parties in exchange for brokerage services.
On October 9, 2023, the stockholders approved the Company's 2023 Equity Incentive Plan (the “2023 Plan”) at its Annual Meeting of Stockholders held in October 2023, the Company's Compensation Committee awarded 908,852 Restricted Stock Units (“RSU's”) to various employees of the Company. The RSU's were immediately vested, and the total value of the award was $345,000 based upon the closing price of $0.3796 of the Company's stock on October 9, 2023. The 2023 Plan having been approved by stockholders, 908,852 shares of the Company's common stock were issued during the 13 weeks ended March 30, 2024.
On February 23, 2024, the Company entered into Unit Purchase Agreements with two otherwise unaffiliated third-party investors, pursuant to which each Investor agreed to purchase 408,163 units of securities from the Company, at a price per Unit of $0.7350, for an aggregate purchase price of $300,000 per investor for an aggregate price of $600,000. Each Unit consists of one share of the Company’s common stock and one warrant to purchase an additional share of common stock. The per-Unit price is allocated as follows: $0.61 per share of common stock and $0.125 per Warrant. The Warrant has a three-year term and will be immediately exercisable. Each Warrant is exercisable at $0.61 per share. The Company intends to use the proceeds from the Unit Purchases for its working capital needs. Further, the Company issued an additional 40,816 shares of its common stock to another party in exchange for brokerage services rendered.
On March 4, 2024, the Company entered into a two-year Consulting Agreement (the “Consulting Agreement”) with Jon Isaac, pursuant to which he will provide a variety of services to the Company. In connection with the Consulting Agreement, the Company issued to Mr. Isaac 200,000 restricted shares of its common stock (see Note 18).
On March 22, 2024, pursuant to the terms and conditions of a promissory note, the Company converted $183,000 of obligations into 300,000 shares of the Company's common stock (see Note 11).
On March 25, 2024, pursuant to the terms and conditions of a promissory note, the Company converted $183,000 of obligations into 300,000 shares of the Company's common stock (see Note 11).
As of March 30, 2024, and December 30, 2023, there were 7,551,379 and 4,957,647 shares, respectively, of common stock issued and outstanding.
Equity Offerings: The Company's 2023 Plan, which was adopted by the Board in August 2023 and approved by the stockholders at the 2023 Annual Meeting of Stockholders, replaces the 2016 Plan, which replaced the 2011 Plan. Under the 2023 Plan, the maximum aggregate number of shares, which may be subject to or delivered under Awards granted under the Plan is two million (2,000,000) shares. Awards may be in the form of a Stock Award, Option, Stock Appreciation Right, Stock Unit, or Other Stock-based Award granted in accordance with the terms of the respective Plan. During the 13 weeks ended March 30, 2024, the Company recognized $345,000 in share-based compensation expense related to the 908,852 RSU's that were awarded and immediately vested (see above).
17

Table of Contents
The Company's 2016 Plan authorizes the granting of awards in any of the following forms: (i) incentive stock options, (ii) nonqualified stock options, (iii) restricted stock awards, and (iv) restricted stock units, and expires on the earlier of October 28, 2026, or the date that all shares reserved under the 2016 Plan are issued or no longer available. On November 4, 2020, the Company amended the 2016 Plan to increase the issuance of common shares from 400,000 to 800,000. The vesting period is determined by the Board of Directors at the time of the stock option grant. As of March 30, 2024 and December 30, 2023, 100,000 options were outstanding under the 2016 Plan.
The Company's 2011 Plan authorizes the granting of awards in any of the following forms: (i) stock options, (ii) stock appreciation rights, and (iii) other share-based awards, including but not limited to, restricted stock, restricted stock units or performance shares, and expired on the earlier of May 12, 2021, or the date that all shares reserved under the 2011 Plan are issued or no longer available. As of March 30, 2024 and December 30, 2023, 14,000 were outstanding under the 2011 Plan. No additional awards will be granted under the 2011 Plan.
The fair value of each stock option grant is estimated on the date of grant using the Black-Scholes option pricing model. There were no stock options granted during the 13 weeks ended March 30, 2024.
Additional information relating to all outstanding stock options is as follows:

| Options Outstanding |  | Weighted Average Exercise Price |  | Aggregate Intrinsic Value |  | Weighted Average Remaining Contractual Life
Outstanding at December 30, 2023 | 114,000 |  | $ | 5.68 |  |  | $ | — |  |  | 6.1
Outstanding at March 30, 2024 | 114,000 |  | $ | 5.68 |  |  | $ | 11 |  |  | 5.9
Exercisable at March 30, 2024 | 114,000 |  | $ | 5.68 |  |  | $ | 11 |  |  | 5.9

The Company recognized $0 and $8,000 of share-based compensation expense related to stock options for the 13 weeks ended March 30, 2024 and April 1, 2023, respectively.
As of April 1, 2023, the Company has the Company had no unrecognized share-based compensation expense associated with equity awards.
Series A-1 Preferred Stock
Shares of Series A-1 Preferred Stock are convertible into the Company’s common shares at a ratio of 20:1. No shares were converted during the 13 weeks ended March 30, 2024. As of March 30, 2024 and December 30, 2023, there were 176,230 shares of Series A-1 Preferred Stock outstanding.
Series S Preferred Stock
On December 28, 2022 the Company acquired Soin Therapeutics by way of merger. In connection with this transaction, with a potential value of up to $30 million, the Company tendered 100,000 shares of the Company's Series S Convertible Preferred Stock. Shares of Series S Convertible Preferred Stock are convertible into the Company’s common shares at a ratio of 1:1. As of March 30, 2024 and December 30, 2023, there were 100,000 shares of Series S Convertible Preferred Stock outstanding.
Note 14: Mezzanine Equity
During the 13 weeks ended March 30, 2024, the Company reclassified approximately $2.7 million from mezzanine equity to current liabilities, and approximately $8.0 million from mezzanine equity to permanent equity (see Note 3). Consequently, as of March 30, 2024, the outstanding balance in mezzanine equity was approximately $3.9 million.
Note 15: Earnings Per Share
Net income (loss) per share is calculated using the weighted average number of shares of common stock outstanding during the applicable period. Basic weighted average common shares outstanding do not include shares of restricted stock that have not yet vested, although such shares are included as outstanding shares in the Company’s Consolidated Balance Sheet. Diluted net income (loss) per share is computed using the weighted average number of common shares outstanding and if
18

Table of Contents
dilutive, potential common shares outstanding during the period. Potential common shares consist of the additional common shares issuable in respect of restricted share awards, stock options and convertible preferred stock.
The following table presents the computation of basic and diluted net income (loss) per share (in $000’s, except share and per–share data):

| For the Thirteen Weeks Ended
| March 30, 2024 |  | April 1, 2023
Continuing Operations |  |  |
Basic and diluted |  |  |
Net loss from continuing operations | $ | (2,144) |  |  | $ | (662) |
Weighted average common shares outstanding | 6,308,331 |  | 3,199,061
Basic and diluted loss per share from continuing operations | $ | (0.34) |  |  | $ | (0.21) |
Discontinued Operations |  |  |
Basic and diluted |  |  |
Net income from discontinued operations | $ | — |  |  | $ | 10,747 |
Weighted average common shares outstanding | 6,308,331 |  | 3,199,061
Basic and diluted income per share from discontinued operations | $ | — |  |  | $ | 3.36 |
Total |  |  |
Basic and diluted |  |  |
Net (loss) income | $ | (2,144) |  |  | $ | 10,085 |
Weighted average common shares outstanding | 6,308,331 |  | 3,199,061
Basic and diluted (loss) income per share | $ | (0.34) |  |  | $ | 3.15 |

Potentially dilutive securities totaling 114,000 and 120,000 were excluded from the calculation of diluted earnings per share for the 13 weeks ended March 30, 2024 and April 1, 2023, respectively, because the effects were anti-dilutive based on the application of the treasury stock method. Additionally, 176,230 shares of Series A-1 Preferred Stock, convertible into approximately 3.5 million shares of the Company’s common stock, and 100,000 shares of Series S Preferred Stock, convertible into 3.0 million shares of the Company's commons stock (subject to certain contractual, event-based, and temporal limitations), were excluded from the calculation of diluted earnings per share as, by agreement, these shares could not be converted as of March 30, 2024.
Note 16: Income Taxes
The Company recorded an income tax benefit from continuing operations of approximately $75,000 and $227,000 for the 13 weeks ended March 30, 2024 and April 1, 2023, respectively, and an income tax expense from discontinued operations of approximately $0 and $3.2 million for the 13 weeks ended March 30, 2024 and April 1, 2023, respectively. The Company’s overall effective tax rate was 3.4% and 22.9% for the 13 weeks ended March 30, 2024 and April 1, 2023, respectively. The effective tax rates and related provisional tax amounts vary from the U.S. federal statutory rate primarily due to state taxes and certain non-deductible expenses.
Note 17: Segment Information
The Company operates within targeted markets through two reportable segments for continuing operations: biotechnology and recycling. The Biotechnology segment commenced operations in September 2019 and is focused on development of new and innovative solutions for ending the opioid epidemic ranging from digital technologies to educational advocacy. The Recycling segment includes all fees charged and costs incurred for collecting, recycling and installing appliances for utilities and other customers. The Recycling segment also includes byproduct revenue, which is primarily generated through the recycling of appliances. The nature of products, services and customers for each segment varies significantly. As such, the segments are managed separately. Our Chief Executive Officer has been identified as the Chief Operating Decision Maker (“CODM”). The CODM evaluates performance and allocates resources based on sales and income from operations of each segment. Operating loss represents revenues less cost of revenues and operating expenses, including certain allocated selling, general and administrative costs. There are no intersegment sales or transfers. Due the sale of
19

Table of Contents
Company's Recycling segment during March 2023, it is being presented as discontinued operations for the 13 weeks ended April 1, 2023.
The following tables present the Company's segment information for the 13 weeks ended March 30, 2024 and April 1, 2023 (in $000's):

| Thirteen Weeks Ended
| March 30, 2024 |  | April 1, 2023
Revenues |  |  |
Biotechnology | $ | — |  |  | $ | — |
Discontinued operations | — |  |  | 3,795 |
Total Revenues | $ | — |  |  | $ | 3,795 |
Gross profit |  |  |
Biotechnology | $ | — |  |  | $ | — |
Discontinued operations | — |  |  | (197) |
Total Gross profit | $ | — |  |  | $ | (197) |
Operating loss |  |  |
Biotechnology | $ | (1,806) |  |  | $ | (1,099) |
Discontinued operations | — |  |  | 14,158 |
Total Operating loss | $ | (1,806) |  |  | $ | 13,059 |
Depreciation and amortization |  |  |
Biotechnology | $ | — |  |  | $ | 364 |
Discontinued operations | — |  |  | 96 |
Total Depreciation and amortization | $ | — |  |  | $ | 460 |
Interest (income) expense, net |  |  |
Biotechnology | $ | 252 |  |  | $ | (475) |
Discontinued operations | — |  |  | 181 |
Total Interest expense, net | $ | 252 |  |  | $ | (294) |
Net income (loss) before income taxes |  |  |
Biotechnology | $ | (2,219) |  |  | $ | (889) |
Discontinued operations | — |  |  | 13,976 |
Total Net income before income taxes | $ | (2,219) |  |  | $ | 13,087 |

Note 18: Related Parties
Shared Services
Tony Isaac, the Company’s Chief Executive Officer, is the father of Jon Isaac, President and Chief Executive Officer of Live Ventures and managing member of Isaac Capital Group LLC (“ICG”). Tony Isaac, Chief Executive Officer, and Richard Butler, Board of Directors member of the Company, are members of the Board of Directors of Live Ventures. The Company also shares certain executive, accounting and legal services with Live Ventures. The total services shared were approximately $338,000 and $32,000 for the 13 weeks ended March 30, 2024 and April 1, 2023, respectively. Customer Connexx rents approximately 9,900 square feet of office space from Live Ventures in Las Vegas, Nevada. Effective August 2023, due to the winding down of operations of the Recycling Subsidiaries, the Company ceased leasing office space in the Las Vegas, Nevada facility. The total rent and common area expense was approximately $— and $36,000 for the 13 weeks ended March 30, 2024 and April 1, 2023, respectively.
Notes with Live Ventures and ICG
On February 7, 2024, the Company entered into a promissory notes with each of Live Ventures and ICG. The initial principal amount of each note is $300,000, with an interest rate of 10% per annum. Pursuant to an amendment to each note, $100,000 of principal, and accrued interest thereon, is due on September 7, 2024 for each note, and the balance of each note is due on December 31, 2024. At the Company’s option, the obligation under each note is convertible after the six-
20

Table of Contents
month anniversary thereof at a per-share conversion price of $0.61, subject to standard adjustments for (i) stock dividends and splits, (ii) subsequent rights offerings, and (iii) pro rata distributions. The Company’s board of directors approved the issuance of the two notes on February 7, 2024. As of March 30, 2024, the principal balances outstanding on each of the promissory notes was $300,000.
Isaac Consulting Agreement
On March 4, 2024, the Company entered into a two-year Consulting Agreement with Jon Isaac, pursuant to which he will provide to the Company (the “Services”): (i) strategic financial advice, including growth strategies, capital allocation, and financial restructuring; (ii) sales and business development advice, including for the acquisition of new clients and new products through networking, referrals, and marketing efforts for our prospective products; (iii) in-depth research and market intelligence on specific industries, sectors, and market trends; (iv) financial models and financial analysis to support strategic decision-making; (v) assistance, through site visits, in the preparation of new client offers and bids for proposed projects; (vi) weekly update calls with management to align on progress of objectives and goals; (vii) enhanced non-confidential materials; (viii) business risk management support; and (ix) other services to which the Company and he may agree that will be memorialized in writing if, when, and as needed during the two-year term.
As compensation for the Services, the Company agreed to (i) assign to him two universal life insurance policies that relate to the life of one of the founders of our now-disposed legacy recycling business (the first policy has an accumulated value/surrender value of approximately $3,854 and the second has an accumulated value/surrender value of approximately $468); (ii) contingently tender to him funds in our Canadian counsel’s trust account in the event that the prospective Order of the Court of Appeal for Ontario Canada in the matter styled, Amtim Capital Inc. and Appliance Recycling Centers of America, Case No. COA-23-CV-0156, becomes the final Order of the Court, which amount we estimated not to exceed approximately US$220,000; (iii) issue to him 200,000 restricted shares of our common stock with the per-share value being the average of the Nasdaq historical NOCP closing price during the five trading days prior to our board approving the Consulting Agreement, which shares were awarded from our 2023 Equity Incentive Plan; and (iv) a two-year, straight 10% convertible promissory note in the initial principal amount of $500,000, with a per-share conversion price equivalent to the per-share value of the restricted common stock that he was granted ($1.16). The maturity date of the promissory note is March 4, 2026. The value of the restricted shares was $232,000 on the date issued. As of March 30, 2024, the principal balance outstanding on the promissory note was $500,000.
Note 19: Subsequent event
The Company has evaluated subsequent events through the filing of this Quarterly Report on Form 10-Q and determined that there have been no events that have occurred that would require adjustments to disclosures in its condensed consolidated financial statements.
21

Table of Contents
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations
Management’s Discussion and Analysis of Financial Condition and Results of Operations (“MD&A”) is intended to provide a reader of our financial statements with a narrative from the perspective of our management on our financial condition, results of operations, liquidity and certain other factors that may affect our future results. Dollars stated in thousands, except per–share amounts.
Forward-Looking and Cautionary Statements
This Quarterly Report on Form 10-Q contains “forward-looking statements” within the meaning of the federal securities laws, including Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which involve risks and uncertainties. You can identify forward-looking statements because they contain words such as ‘‘believes,’’ ‘‘expects,’’ ‘‘may,’’ ‘‘will,’’ ‘‘should,’’ ‘‘seeks,’’ ‘‘approximately,’’ ‘‘intends,’’ ‘‘plans,’’ ‘‘estimates’’ or ‘‘anticipates’’ or similar expressions that concern our strategy, plans or intentions. Any statements we make relating to our future operations, performance and results, and anticipated liquidity are forward-looking statements. All forward-looking statements are subject to risks and uncertainties that may change at any time, and, therefore, our actual results may differ materially from those we expected. We derive most of our forward-looking statements from our operating budgets and forecasts, which are based upon many detailed assumptions. While we believe that our assumptions are reasonable, we caution that it is very difficult to predict the impact of known factors, and, of course, it is impossible for us to anticipate all factors that could affect our actual results. Important factors that could cause actual results to differ materially from our expectations, including, without limitation, in conjunction with the forward-looking statements included in this Form 10-Q, are disclosed in “Item 1-Business, Item 1A – Risk Factors” of our Form 10-K and Part II, Item 1A of this Form 10-Q.
We undertake no obligation to publicly update or revise any forward-looking statement as a result of new information, future events or otherwise, except as otherwise required by law. Our MD&A should be read in conjunction with our Form 10-K (including the information presented therein under the caption Risk Factors), together with our Quarterly Reports on Forms 10-Q and other publicly available information. All amounts herein are unaudited.
Overview
We are focused on finding treatments for conditions that cause severe pain and bringing to market drugs with non-addictive pain-relieving properties. In addition, through our now-sold subsidiaries ARCA Recycling, Connexx, and ARCA Canada, we were engaged in the business of recycling major household appliances in North America by providing turnkey appliance recycling and replacement services for utilities and other sponsors of energy efficiency programs. Also, through our now-sold GeoTraq Inc. subsidiary, we were engaged in the development and design of wireless transceiver modules with technology that provides LBS directly from global Mobile IoT networks.
During the periods disclosed in this Quarterly Report, we operated three reportable segments:
•Biotechnology: Our biotechnology segment is focused on finding treatments for conditions that cause severe pain and bringing to market drugs with non-addictive pain-relieving properties.
•Recycling: Our Recycling segment is a turnkey appliance recycling program. We receive fees charged for recycling, replacement and additional services for utility energy efficiency programs and have established 18 Regional Processing Centers (“RPCs”) for this segment throughout the United States and Canada. On March 9, 2023, we entered into a Stock Purchase Agreement, retroactive to March 1, 2023, with VM7 Corporation, a Delaware corporation, under which the Buyer agreed to acquire all of the outstanding equity interests of our Recycling segment. Consequently, the results for this segment are reported as discontinued operations for the 13 weeks ended April 1, 2023.
22

Table of Contents
For the Thirteen Weeks Ended March 30, 2024 and April 1, 2023
Results of Operations
The following table sets forth certain statement of operations items and as a percentage of revenue, for the periods indicated (in $000's):

| 13 Weeks Ended |  | 13 Weeks Ended
| March 30, 2024 |  | April 1, 2023
Statement of Operations Data: |  |  |
Revenues | $ | — |  |  | $ | — |
Cost of revenues | — |  |  | — |
Gross profit | — |  |  | — |
Selling, general and administrative expenses | 1,806 |  |  | 1,099 |
Operating loss | (1,806) |  |  | (1,099) |
Interest income, net | (252) |  |  | 475 |
Unrealized loss on marketable securities | (190) |  |  | (247) |
Other income, net | 29 |  |  | (18) |
Net income (loss) before provision of income taxes | (2,219) |  |  | (889) |
Income tax benefit | (75) |  |  | (227) |
Net income (loss) from continuing operations | (2,144) |  |  | (662) |
Income from discontinued operations | — |  |  | 13,976 |
Income tax provision (benefit) for discontinued operations | — |  |  | 3,229 |
Net income (loss) from discontinued operations | — |  |  | 10,747 |
Net loss | $ | (2,144) |  |  | $ | 10,085 |

The following tables set forth revenues for key product and service categories, percentages of total revenue and gross profits earned by key product and service categories and gross profit percent as compared to revenues for each key product category indicated (in $000's):

| 13 Weeks Ended |  | 13 Weeks Ended
| March 30, 2024 |  | April 1, 2023
| Net Revenue |  | Percent of Total |  | Net Revenue |  | Percent of Total
Revenue |  |  |  |  |  |  |
Revenue from discontinued operations | $ | — |  |  | — | % |  | $ | 3,795 |  |  | 100.0 | %
Biotechnology | — |  |  | — | % |  | — |  |  | — | %
Total revenue | $ | — |  |  | — | % |  | $ | 3,795 |  |  | 100.0 | %

| 13 Weeks Ended |  | 13 Weeks Ended
| March 30, 2024 |  | April 1, 2023
| Gross Profit |  | Gross Profit Percentage |  | Gross Profit |  | Gross Profit Percentage
Gross Profit |  |  |  |  |  |  |
Gross profit from discontinued operations | $ | — |  |  | — | % |  | $ | (197) |  |  | -5.2 | %
Biotechnology | — |  |  | — | % |  | — |  |  | — | %
Total gross profit | $ | — |  |  | — | % |  | $ | (197) |  |  | -5.2 | %

Revenue
Revenue decreased by approximately $3.8 million for the 13 weeks ended March 30, 2024, as compared to the 13 weeks ended April 1, 2023. The decrease is due to the disposition of our Recycling segment as of March 1, 2023.
23

Table of Contents
Cost of Revenue
Cost of revenue decreased by approximately $4.0 million for the 13 weeks ended March 30, 2024, as compared to the 13 weeks ended April 1, 2023. The decrease is due to the disposition of our Recycling segment as of March 1, 2023.
Selling, General and Administrative Expense
Selling, general and administrative expenses increased by approximately $700,000, or 64.3%, for the 13 weeks ended March 30, 2024, as compared to the 13 weeks ended April 1, 2023, primarily due to increased amortization costs relating to the Soin intangibles, as well as stock-based compensation expense recognized due to the grants of RSU’s (see Note 13). This increase relates only to continuing operations.
Interest Expense, net
Interest expense, net increased by approximately $727,000 for the 13 weeks ended March 30, 2024, as compared to the 13 weeks ended April 1, 2023 primarily due to no longer accreting the discounts in connection with the promissory note with SPYR and the receivable from VM7.
Unrealized Loss on Marketable Securities
Unrealized loss on marketable securities for the 13 weeks ended March 30, 2024 was approximately $190,000, as compared to a loss of approximately $247,000 for the 13 weeks ended April 1, 2023. An unrealized gain or loss on marketable securities is recorded to mark to fair value securities received in connection to the sale of GeoTraq..
Segment Performance
We report our business in the following segments: Biotechnology and discontinued operations. We expect revenues and profits for our biotechnology segment to be driven by the development of pharmaceuticals that treat the root cause of pain but are non-opioid painkillers. We include Corporate expenses within the Biotechnology segment. As discussed above, we sold our Recycling segment in March 2023, and detail its results as discontinued operations below.
Operating loss by operating segment, is defined as loss before net interest expense, other income and expense, provision for income taxes ($000’s).

| 13 Weeks Ended March 30, 2024 |  | 13 Weeks Ended April 1, 2023
| Biotechnology |  | Discontinued Operations |  | Total |  | Biotechnology |  | Discontinued Operations |  | Total
Revenue | $ | — |  |  | $ | — |  |  | $ | — |  |  | $ | — |  |  | $ | 3,795 |  |  | $ | 3,795 |
Cost of revenue | — |  |  | — |  |  | — |  |  | — |  |  | 3,992 |  |  | 3,992 |
Gross profit | — |  |  | — |  |  | — |  |  | — |  |  | (197) |  |  | (197) |
Selling, general and administrative expense | 1,806 |  |  | — |  |  | 1,806 |  |  | 1,099 |  |  | (14,355) |  |  | (13,256) |
Operating loss | $ | (1,806) |  |  | $ | — |  |  | $ | (1,806) |  |  | $ | (1,099) |  |  | $ | 14,158 |  |  | $ | 13,059 |

Biotechnology Segment
Our biotechnology segment incurred expenses of approximately $1.8 million and $1.1 million related to employee costs and professional services related to research, corporate services, and stock-based compensation expense, as well as amortization of the Soin intangibles for the 13 weeks ended March 30, 2024 and the 13 weeks ended April 1, 2023, respectively.
Discontinued Operations
Discontinued operations consists of our Recycling segment, which was disposed of effective March 1, 2023. Revenue for the 13 weeks ended March 30, 2024 decreased by approximately $3.8 million as compared to the prior year period, which was due to the disposition of our Recycling segment as of March 1, 2023.
24

Table of Contents
Operating loss for the 13 weeks ended March 30, 2024, increased by approximately $700,000 as compared to the prior year period. The increase is primarily due increased amortization of the Soin intangible, as well as stock-based compensation expense recognized due to the grants of RSU’s (seen Note 13).
Liquidity and Capital Resources
Overview
As of March 30, 2024, our cash on hand was $61,000. We intend to raise funds to support future development of JAN 123 either through capital raises or structured arrangements.
Our ability to continue as a going concern is dependent upon the success of future capital raises or structured settlements to fund the required testing to obtain FDA approval of JAN 123, as well as to fund our day-to-day operations. The accompanying financial statements do not include any adjustments that might be necessary should we be unable to continue as a going concern. While we will actively pursue these additional sources of financing, management cannot make any assurances that such financing will be secured.
Cash Flows
During the 13 weeks ended March 30, 2024, cash used in operations was approximately $544,000, compared to cash provided by operations of approximately $2.4 million during the 13 weeks ended April 1, 2023. Cash provided by discontinued operations during the 13 weeks ended April 1, 2023 was approximately $2.3 million, while cash provided by continuing operations was approximately $106,000. The decrease in cash was primarily due to results of operations as discussed above.
Cash used in investing activities was approximately $0 and $156,000, respectively, for the 13 weeks ended March 30, 2024 and the 13 weeks ended April 1, 2023. Cash used in investing activities for the 13 weeks ended March 30, 2024 was all associated with discontinued operations and was related to purchases of property and equipment. Cash used in investing activities for the 13 weeks ended March 30, 2024 was all associated with discontinued operations and was related to purchases of property and equipment.
Cash provided by financing activities was $600,000 for the 13 weeks ended March 30, 2024, and relates to proceeds received from warrants converted to our common stock. Cash used in financing activities was approximately $2.0 million for the 13 weeks ended April 1, 2023. Cash used in financing activities from discontinued operations for the 13 weeks ended April 1, 2023 was approximately $2.2 million and was primarily due to the repayment of debt obligations. Cash provided financing activities from continued operations for the 13 weeks ended April 1, 2023 was approximately $163,000 and was related to $368,000 in proceeds from equity financing, partially offset by $205,000 in debt repayments..
Sources of Liquidity
We continue to face a challenging competitive environment as we continue to focus on raising capital and managing expenses. We reported a net loss of approximately $2.1 million from continuing operations in for the 13 weeks ended March 30, 2024, and a net loss from continuing operations of approximately $662,000 for the 13 weeks ended April 1, 2023 primarily due to increased amortization expense of the Soin intangible, stock-based compensation expense of $345,000, and an increase in interest expense of approximately $700,000 due to due to no longer accreting the discounts in connection with the promissory note with SPYR and the receivable from VM7. Additionally, the Company has total current assets of approximately $1.2 million and total current liabilities of approximately $8.1 million resulting in a net negative working capital of approximately $6.9 million. Cash used in continuing operations was approximately $544,000.
Future Sources of Cash; Phase 2b Trials, New Acquisitions, Products, and Services
We may require additional debt financing and/or capital to finance new acquisitions, conduct our Phase IIb clinical trials, or consummate other strategic investments in our business. No assurance can be given any financing obtained may not further dilute or otherwise impair the ownership interest of our existing stockholders.
Item 3. Quantitative and Qualitative Disclosures about Market Risk
Market Risk and Impact of Inflation
Interest Rate Risk. We do not believe there is any significant risk related to interest rate fluctuations on our short and long-term fixed rate debt.
25

Table of Contents
We do not hold any derivative financial instruments, nor do we hold any securities for trading or speculative purposes.
Item 4. Controls and Procedures
Evaluation of Disclosure Controls and Procedures
Evaluation of Disclosure control and Procedures. We carried out an evaluation, under the supervision and with the participation of our management, including our principal executive officer and principal financial officer, of the effectiveness of our disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) to ensure that information required to be disclosed in reports filed under the Securities Exchange Act of 1934 is recorded, processed, summarized and reported within the required time periods and is accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate to allow timely decisions regarding required disclosure..
Based upon that evaluation, our principal executive officer and principal financial officer concluded that, as of March 30, 2024, the period covered in this report, our disclosure controls and procedures were not effective because of the material weaknesses discussed below.
In light of the conclusion that our internal disclosure controls are ineffective as of March 30, 2024, we have applied procedures and processes as necessary to ensure the reliability of our financial reporting in regard to this Quarterly Report. Accordingly, the Company believes, based on its knowledge, that: (i) this Quarterly Report does not contain any untrue statement of a material fact or omit a material fact; and (ii) the financial statements, and other financial information included in this Quarterly Report, fairly present in all material respects our financial condition, results of operations and cash flows as of and for the periods presented in this Quarterly Report.
Management’s Report on Internal Control Over Financial Reporting. Our management is responsible for establishing and maintaining adequate internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)). Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.
Our management assessed the effectiveness of our internal control over financial reporting as of March 30, 2024. In making this assessment, we used the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission (“COSO”) in 2013 regarding Internal Control – Integrated Framework. Based on our assessment using those criteria, our management concluded that our internal control over financial reporting was not effective as of March 30, 2024.
Management noted material weaknesses in internal control when conducting their evaluation of internal control as of March 30, 2024. (1) Insufficient written documentation of our internal control policies and procedures. Written documentation of key internal controls over financial reporting is a requirement of Section 404 of the Sarbanes-Oxley Act; and (2) Insufficient resources to maintain adequate segregation of duties and maintain its internal control environment.
These material weaknesses remained outstanding as of the filing date of this Form 10-Q and management is currently working to remedy these outstanding material weaknesses.
The Company’s management, including the Company’s CEO and CFO, does not expect that the Company’s disclosure controls and procedures or the Company’s internal controls over financial reporting will prevent or detect all error and all fraud. A control system, regardless of how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system will be met. These inherent limitations include the following: judgements in decision-making can be faulty, and control and process breakdowns can occur because of simple errors or mistakes, controls can be circumvented by individuals, acting alone or in collusion with each other, or by management override, the design of any system of controls is based in part on certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions, over time, controls may become inadequate because of changes in conditions or deterioration in the degree of compliance with policies or procedures. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, have been detected.
26

Table of Contents
Changes in Internal Control Over Financial Reporting. There were no changes in the Company’s internal control over financial reporting during the fiscal year ended March 30, 2024 that have materially affected, or are reasonably likely to materially affect, the Company’s internal control over financial reporting.
27

Table of Contents
PART II. Other Information
Item 1. Legal Proceedings
The information in response to this item is included in Note 12, Commitments and Contingencies, to the Consolidated Financial Statements included in Part I, Item 1, of this Form 10-Q.
Item 1A. Risk Factors
We are a smaller reporting company as defined by Rule 12b-2 of the Securities Exchange Act of 1934 and are not required to provide the information under this item. However, in light of the SEC Complaint, the Company provides the following additional risk factors, which supplements the risk factors previously disclosed by the Company in Part I, Item 1A, Risk Factors, of the 2023 10-K.
We may not be able to maintain compliance with the continued listing requirements of The Nasdaq Capital Market.
Our common stock is listed on The Nasdaq Capital Market. In order to maintain that listing, we must satisfy minimum financial and other requirements including, without limitation, a requirement that our closing bid price be at least $1.00 per share and net stockholders’ equity of not less than $2.5 million. If we fail to continue to meet all applicable continued listing requirements for The Nasdaq Global Market in the future and Nasdaq determines to delist our common stock, the delisting could adversely affect the market liquidity of our common stock, our ability to obtain financing to repay debt, and fund our operations.
Item 2. Unregistered Sales of Equity Securities and Use of funds
None.
Item 3. Defaults Upon Senior Securities
None.
Item 4. Mine Safety Disclosures
None.
Item 5. Other Information.
None.
Item 6. Exhibits.
Index to Exhibits
28

Table of Contents

Exhibit Number |  | Exhibit Description |  | Form |  | File Number |  | Exhibit Number |  | Filing Date
31.1 | * | Certification of the Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 |  |  |  |  |  |  |  |
31.2 | * | Certification of the Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 |  |  |  |  |  |  |  |
32.1 | * | Certification of the President and Chief Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 |  |  |  |  |  |  |  |
32.2 | * | Certification of the Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 |  |  |  |  |  |  |  |
101.INS | * | Inline XBRL Instance Document |  |  |  |  |  |  |  |
101.SCH | * | Inline XBRL Taxonomy Extension Schema Document |  |  |  |  |  |  |  |
101.CAL | * | Inline XBRL Taxonomy Extension Calculation Linkbase Document |  |  |  |  |  |  |  |
101.DEF | * | Inline XBRL Taxonomy Extension Definition Linkbase Document |  |  |  |  |  |  |  |
101.LAB | * | Inline XBRL Taxonomy Extension Label Linkbase Document |  |  |  |  |  |  |  |
101.PRE | * | Inline XBRL Taxonomy Extension Presentation Linkbase Document |  |  |  |  |  |  |  |
104 |  | Cover Page Interactive Data File (formatted in Inline XBRL and contained in Exhibit 101) |  |  |  |  |  |  |  |

________________________
*Filed herewith.
29

Table of Contents
SIGNATURES
Pursuant to the requirements of Section 13 or Section 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on our behalf by the undersigned, thereunto duly authorized.

|  | JanOne Inc.
|  | (Registrant)
Date: | May 3, 2024 | By: | /s/ Tony Isaac
|  |  | Tony Isaac
|  |  | Chief Executive Officer
|  |  | (Principal Executive Officer)
Date: | May 3, 2024 | By: | /s/ Virland A. Johnson
|  |  | Virland A. Johnson
|  |  | Chief Financial Officer
|  |  | (Principal Financial and Accounting Officer)

30